FDA 2024: Watch For Trial-Diversity Guidance, Final Quality Systems Rewrite
Executive Summary
Industry observers at RAPS Convergence in Montreal last week said the FDA’s agenda for 2024 is likely to include increased emphasis on MDUFA goals, enhanced cybersecurity requirements, the new QMSR, and more.
You may also be interested in...
‘Refuse to Accept’ Decisions For Cyber Devices To Begin In October
The US FDA is giving sponsors a grace period of six months before it will issue “refuse to accept” decisions for premarket submissions for cyber devices that lack the information required under recent cyber amendments.
Game Time: FDA Releases Review Timeline Goals Set By MDUFA V
This exclusive infographic shows new review timelines the FDA announced for FY 2023 now that MDUFA V has been ratified.
FDA Draft Guidance Takes Aim At Racial, Ethnic Disparities In Clinical Trials
The US agency has outlined steps industry can take to ensure clinical trials include a broader representation of underrepresented racial and ethnic groups.